+ Watch IMUC
on My Watchlist
In December this stock nearly doubled after the company issued a PR claiming that the EMA provided them with positive regulatory feedback regarding the proposed phase III trial of ICT-107. I read the PR a few times and I'm not sure whether it contained any information of any kind. The only positive feedback of interest from a regulatory body regarding a clinical trial would relate to a clinical trial that has already been completed, not one that has not yet been initiated. The only exceptions would be an SPA or a reduction in the number of clinical trials for approval.I expect ImmunoCellular to go the way of Cel-Sci, Arca, and Opexa in terms of embarking upon a futile phase III trial that will require countless rounds of dilution and at least one reverse split over at least five years prior to completion. I'm only dropping a green thumb here because it seems like retail is begging to be kicked in the teeth again.
a la dendreon
It is going to hit 6 dollars by the end of 2014. Biotechnology is on the rise.
according to the company, we can expect results from the ict-107 phase II trail.
several good products progressing in the pipeline.
Strong pipeline. low requirement for approval. Just needs to "same or better" then current treatments for GBMF (Brain cancer). and current treatment is frankly poor. Chance of no approval is almost zero.
Research in pipeline
It was picked by www.hechtsoft.de Trade Alerts.
Has a cancer vaccine that appears very promising.
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions